消化器疾患治療薬市場：流通チャネル、投与経路、用途別-2024-2030年の世界予測

消化器疾患治療薬市場規模は2023年に401億8,000万米ドルと推計され、2024年には418億2,000万米ドルに達し、CAGR 4.00%で2030年には529億1,000万米ドルに達すると予測されます。

消化器疾患治療薬の世界市場

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは消化器疾患治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、消化器疾患治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-消化器疾患治療薬市場の市場規模および予測は？

2-消化器疾患治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-消化器疾患治療薬市場における技術動向と規制の枠組みは？

4-消化器疾患治療薬市場における主要ベンダーの市場シェアは？

5-消化器疾患治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 胃腸疾患の罹患率の増加
    • セルフメディケーションと再生医療への需要の高まり
    • 胃腸疾患の治療における生物学的製剤の採用の増加
  • 抑制要因
    • 消化器疾患に関連する社会経済的負担の増大
  • 機会
    • 製薬会社による研究開発投資の増加
    • 胃腸疾患の予防と治療に対する政府の取り組み
  • 課題
    • 特許失効件数の増加
• 市場セグメンテーション分析
• 市場動向分析
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み

第6章 消化器疾患治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第7章 消化器疾患治療薬市場：投与経路別

• 静脈内
• オーラル

第8章 消化器疾患治療薬市場：用途別

• クローン病
• 胃食道逆流症
• 潰瘍性大腸炎

第9章 南北アメリカの消化器疾患治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の消化器疾患治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの消化器疾患治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

• 主要な企業プロファイル
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Olympus Corporation
  • Ovesco Endoscopy AG
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.
• 主要な製品ポートフォリオ

第14章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET DYNAMICS
• FIGURE 7. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 8. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 10. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 12. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
• FIGURE 22. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

• TABLE 1. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 6. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 10. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 13. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. CANADA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. CHINA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. INDIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. INDIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. INDIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. MALAYSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. SOUTH KOREA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. TAIWAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. THAILAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. VIETNAM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. DENMARK GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EGYPT GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. FINLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. FRANCE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. GERMANY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. ISRAEL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. ITALY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. ITALY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. ITALY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. NETHERLANDS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. NIGERIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NORWAY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. POLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. POLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. POLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. QATAR GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. QATAR GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. QATAR GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. RUSSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. SAUDI ARABIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SPAIN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SWEDEN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SWITZERLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. TURKEY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. UNITED KINGDOM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
• TABLE 144. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 145. GASTROINTESTINAL DISEASES THERAPEUTICS MARKET LICENSE & PRICING

[189 Pages Report] The Gastrointestinal Diseases Therapeutics Market size was estimated at USD 40.18 billion in 2023 and expected to reach USD 41.82 billion in 2024, at a CAGR 4.00% to reach USD 52.91 billion by 2030.

Global Gastrointestinal Diseases Therapeutics Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gastrointestinal Diseases Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gastrointestinal Diseases Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Diseases Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Cipla Inc., Eisai Co. Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Novartis AG, Olympus Corporation, Ovesco Endoscopy AG, Takeda Pharmaceutical Company Limited, and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Diseases Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
• Route of Administration
  • Intravenous
  • Oral
• Application
  • Crohn's Disease
  • Gastroesophageal Reflux Disease
  • Ulcerative Colitis
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Gastrointestinal Diseases Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gastrointestinal Diseases Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Gastrointestinal Diseases Therapeutics Market?

4. What is the market share of the leading vendors in the Gastrointestinal Diseases Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Gastrointestinal Diseases Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Gastrointestinal Diseases Therapeutics Market, by Region

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of gastrointestinal diseases
    • 5.1.1.2. Rising demand for self-medication and regenerative medicines
    • 5.1.1.3. Increasing adoption of biologics for treatment of gastrointestinal diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Rising socio-economic burden associated with GI disorders
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising investments in R&D by pharmaceutical companies
    • 5.1.3.2. Government initiatives to prevent and treat gastrointestinal diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Increasing number of patent expirations
• 5.2. Market Segmentation Analysis
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework

6. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel

• 6.1. Introduction
• 6.2. Hospital Pharmacies
• 6.3. Online Pharmacies
• 6.4. Retail Pharmacies

7. Gastrointestinal Diseases Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Oral

8. Gastrointestinal Diseases Therapeutics Market, by Application

• 8.1. Introduction
• 8.2. Crohn's Disease
• 8.3. Gastroesophageal Reflux Disease
• 8.4. Ulcerative Colitis

9. Americas Gastrointestinal Diseases Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Gastrointestinal Diseases Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Gastrointestinal Diseases Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

• 13.1. Key Company Profiles
  • 13.1.1. Abbott Laboratories
  • 13.1.2. AstraZeneca PLC
  • 13.1.3. Bayer AG
  • 13.1.4. Biogen Inc.
  • 13.1.5. Boehringer Ingelheim International GmbH
  • 13.1.6. Cipla Inc.
  • 13.1.7. Eisai Co. Ltd.
  • 13.1.8. Eli Lilly and Company
  • 13.1.9. GlaxoSmithKline PLC
  • 13.1.10. Johnson & Johnson Services Inc.
  • 13.1.11. Novartis AG
  • 13.1.12. Olympus Corporation
  • 13.1.13. Ovesco Endoscopy AG
  • 13.1.14. Takeda Pharmaceutical Company Limited
  • 13.1.15. UCB S.A.
• 13.2. Key Product Portfolio

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing